List of Oncology Clinical Trials:

  • A Randomized, Phase II, Placebo Controlled Study of GDC-0068, An Inhibitor to AKT, In Combination with Fluorophrimidine plus Oxaliplatin in patients with Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma.

Sponsor: Genentech Inc, USA

Protocol Number: GO28341


  • A Randomized, Phase ll, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating The Efficacy and Safety of MetMab in Combination with Either Bevacizumab + Platinum + Paclitaxel or Pemetrexed + Platinum as First- Line Treatment in Patients with Stage lllB or  lV non- Squamous non-small Cell Lung Cancer (NSCLC)

Sponsor: Genentech Inc, USA

Protocol Number: GO27821


  • An open label, multicenter extension study of Onartuzumab in patients with solid tumors on study treatment previously enrolled in an F.Hoffmann-La-Roche and/or Genetech Sponsored Study.

Sponsor: Genentech Inc, USA

Protocol Number: GO29646


  • A Phase II, Double-Blind, Placebo Controlled, Randomized Study of GDC-0941 or GDC-0980 with Fulvestrant versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy.

Sponsor: Genentech Inc, USA

Protocol Number: GDC4950g (FERGI)


  • A Multicenter, Randomized, Double-blind Phase III trial to evaluate Efficacy and Safety of BI695502 plus Chemotherapy versus Avastin plus Chemotherapy in Patients with Advanced non- Squamous Non Small Cell Lung Cancer.

Sponsor: Boehringer Ingelheim

Protocol Number: 1302.5



  • A Phase III, Randomized, Double-blind, multi-center, multi-national trial to evaluate efficacy and safety of BI695500 versus Rituximab as a First-line Immunotherapy Treatment in Patients with Low Tumor burden Follicular Lymphoma.

Sponsor: Boehringer Ingelheim

Protocol Number: BI1301.6


  • A Randomized, Controlled, Double-blind Phase lll Trial to Compare the Efficacy, Safety and Pharmacokinetics of GP2013 plus Cyclophosphamide, Vincristine, Prednisolone (CVP) vs MabThera plus CVP, Followed by GP2013 or MabThera Maintenance Therapy in Patients with Previously Untreated, Advanced Stage Follicular Lymphoma.

Sponsor: Sandoz

Protocol Number: GP13-301 (ASSIST-FL)


  • A Phase III Randomized, Double-blind Study of PF-06439535 Plus Paclitaxel-Carboplatin and Bevacizumab plus Paclitaxel-Carboplatin for the First-Line Treatment of Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer

Sponsor: Pfizer

Protocol Number: B7391003


  • A Randomized, Double-blind, Phase III Study Comparing Biosimilar Rituximab (RTXM83) Plus CHOP Chemotherapy versus a Reference Rituximab Plus CHOP (R-CHOP) in patients with diffuse large B-cell Lymphoma (DLBCL) given as first Line

Sponsor: Innogene

Protocol Number: RTXM83-AC-01-11


  • A Randomized, Double-Blind Phase 1/2 Study of INCB039110 in Combination With Erlotinib Versus Erlotinib Alone in Subjects With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer Whose Tumors Have Epidermal Growth Factor Receptor-Activating Mutations

Sponsor: Incyte Coorporation

Protocol Number: INCB 39110-205


  • A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab versus Treatment of Physician’s Choice Monotherapy for Metastatic Triple Negative Breast Cancer (mTNBC)

Sponsor: MSD

Protocol Number: MK3475-119


  • A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi cycle Chemotherapy

Sponsor: Amgen

Protocol Number: 20070782